RCS - Oxford BioDynamics - OBD to present at PMWC 2026

Oxford BiodynamicsAnnouncement

Yesterday 09:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260303:nRSC1170Va&default-theme=true

RNS Number : 1170V  Oxford BioDynamics PLC  03 March 2026

 

 

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

OBD to present at PMWC 2026

Oxford, UK - 3 March 2026 - Oxford BioDynamics Plc (AIM: OBD, the Company), a
precision clinical diagnostics company bringing specific and sensitive tests
to the practice of medicine based on its EpiSwitch® 3D genomics platform,
announces a presentation by its Chief Data Officer Dr Ewan Hunter in the AI
and Data Sciences Showcase at Precision Medicine World Conference (PMWC) 2026
in Silicon Valley.

Dr Hunter's presentation, in Showcase Track S1, 11.30am - 12.00pm on 4 March,
will be titled "Unfolding the Genome's "Natural Intelligence" with EpiSwitch
Orion". Ewan will introduce the Group's newly-launched EpiSwitch Orion
platform, explaining how it can be used to turn static DNA information into
actionable insights for targeted therapies.

About EpiSwitch Orion

EpiSwitch® Orion is a high-resolution 3D-genomic tool that turns static DNA
data into real-time clinical insights. While most tests only look at the
protein-coding regions of a person's DNA, Orion analyzes the 98% of the genome
often called "dark matter". This dark matter is a critical "control system"
that acts like a wiring diagram for our genes. By finding changes in specific
EpiSwitch anchor sites within these regions, Orion reveals how the genome's
physical structure turns genes on or off. This allows it to bridge the gap
between standard Next-Generation Sequencing (NGS) or Genome-Wide Association
Studies (GWAS) and the actual functional state of a disease or drug response.

The platform is powered by the EpiSwitch Knowledgebase, the world's largest 3D
genomics knowledge graph, which uses Artificial Intelligence (AI) to link over
15 million high-confidence genomic interactions to clinical action. By
decoding the "wiring problems" that lead to illness, Orion helps
pharmaceutical, biotech, and academic partners group patients more accurately,
improve treatments and speed up the delivery of precision medicine for cancer,
autoimmune diseases and neurological conditions.

About PMWC 2026

Known as the "Davos of Precision Medicine", PMWC is the largest annual
conference dedicated to precision medicine. Its mission is to bring together
recognised leaders, top global researchers and medical professionals, and
innovators across the healthcare and biotechnology sectors to showcase
practical content that helps close the knowledge gap between different
sectors, thereby catalyzing cross-functional fertilization and collaboration
in an effort to accelerate the development and spread of precision medicine.

This year's conference will feature contributions from many prominent leaders
and innovators, including Greg Brockman (Co-founder & President, OpenAI),
Judy Faulkner (Founder & CEO, Epic), Vinod Khosla (Founder, Khosla
Ventures), Priscilla Chan (Co-founder, Biohub), Steve Wozniak (Co-founder,
Apple) and Nobel Laureates Mary Brunkow and W.E. Moerner.

-Ends-

For further details please contact:

  Oxford BioDynamics Plc                                Tel: +44 (0)1865 518910
 Iain Ross Executive Chairman

 Paul Stockdale, CFO
 Singer Capital Markets - Nominated Adviser and Broker  Tel: +44 (0)20 7496 3095
 Phil Davies / Anastassiya Eley
 OAK Securities - Joint Broker                          Tel: +44 (0)20 3973 3678
 Matthew Clarke / Tim Dainton / Calvin Man
 Camarco - Financial PR                                 Tel: +44 (0)20 3757 4980
 Marc Cohen / Tilly Butcher / Fergus Young              OBDFinancial@camarco.co.uk

 

 

Notes to Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company,
advancing personalized healthcare by developing and commercializing precision
clinical diagnostic tests for life-changing diseases.

Currently, OBD has two commercially available products: the EpiSwitch® PSE
(https://url.avanan.click/v2/___http:/www.94percent.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjphZTRmOjE1ZmE3ZTA1NmFmMzlmYjIzZmFhOGU1NTc5MWI0OTdiODZmMjVmOTFlOWQ2YjBiZTM3YmNmMTMxMGYxOTcxMjI6cDpU)
 (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjpjZGI4OjQ3ZWJmMjU3YzNhNjYzYzNiYWVjZGNlMTJjZDM5ZGZkYzBlNmQyNTc0OTdlZWU4ZGI4ODFlYzU1OWZmN2JmMWE6cDpU)
 (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or absence of
prostate cancer. CiRT is a highly accurate (85%) predictive response test to
immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker technology, the
EpiSwitch® platform, which enables screening, evaluation, validation and
monitoring of biomarkers to diagnose patients or determine how individuals
might respond to a disease or treatment.

EpiSwitch® Orion is a high-resolution 3D-genomic tool that turns static DNA
data into real-time clinical insights by analyzing both coding and non-coding
regions for changes in specific anchor sites. This allows it to bridge the gap
between standard Next-Generation Sequencing (NGS) or Genome-Wide Association
Studies (GWAS) and the actual state of a disease or drug response in both
blood and tissue samples in multiple organisms. The platform is powered by the
EpiSwitch® Knowledgebase, the world's largest 3D genomics knowledge graph,
which uses Artificial Intelligence (AI) to link over 15 million genomic
interactions to clinical action.

OBD's clinical smart tests have the potential to be used across a broader
range of indications, and new tests are being developed in the areas of
oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US
operations and clinical laboratory are in Maryland, USA, along with a
reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more
information, please visit the Company's website, www.oxfordbiodynamics.com
(https://url.avanan.click/v2/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6Njo3YmRiOmUxODM2ZWZhYmIxNjdhMjFiNTMxOThjNjE0YzMwYzg5YzA1MjI2MmYxMGY0ZTU1MzdjYzdlYzg1NDA5ZTcyOWU6cDpU)
,  X (@OxBioDynamics) or LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjozM2I4OmVmNzdkN2M0NmYxZDg3ODc0MWQ1NDEyMGQ4MjAxOWVmMTg4ZTMzNWY4MTA5NGE3NTE5ZDdlNWIwNjI5MTRhMTM6cDpU)
.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAKXLBBQXLFBBE



            Copyright 2019 Regulatory News Service, all rights reserved